Endocrinology, Gastroenterology, Physiology
Conditions
Keywords
Incretin hormones, Glucose-insulinotropic peptide, Glucagon-like peptide-1, Gastric emptying, Appetite, Glucose disposal, Gut hormones
Brief summary
Academic phase 1 study which investigates the effects of the two incretin hormones glucose-insulinotropic peptide (GIP) and glucagon-like peptide-1 (GLP-1) on gastric emptying, appetite, insulin release and glucose disposal in the body. The hypothesis is that incretin hormones not only stimulate insulin release but also inhibits gastric emptying. This effect can be utilized for further drug development.
Detailed description
Effects of GIP and GLP-1 on gastric emptying, appetite control and insulin release in relation to glucose levels in the bloodstream. Infusions of GIP and GLP-1 are given under simultaneous gastric emptying study and appetite questionnaires and blood sampling for analysis of insulin, glucose, and other gut hormones such as glucagon, ghrelin, and PYY, as well as those administered, GIP and GLP-1.
Interventions
OTHERGlucose-insulinotropic peptide, Glucagon-like peptide-1
GIP 2 and 5 pmol/kg min GLP-1 0.7 pmol/kg min
Sponsors
Karolinska Institutet
University of Copenhagen
Uppsala University
Study design
Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
BASIC_SCIENCE
Masking
DOUBLE (Subject, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
18 Years to 50 Years
Healthy volunteers
Yes
Inclusion criteria
* Men and women * 18-50 years old; * otherwise healthy and HIV and HCB, HCV negative
Exclusion criteria
* Age \>50, * all types of diseases and drug users.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Gastric emptying rate | 2005-2006 |
Secondary
| Measure | Time frame |
|---|---|
| Plasma glucose, insulin release, appetite | 2005-2006 |
Countries
Sweden
Outcome results
None listed